{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT00126308: Phase 4 Interventional Terminated HIV-Associated Lipodystrophy
(2005)
Source URL:
First approved in 1985
Source:
NDA020263
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA020353
(1976)
Source URL:
First approved in 1976
Source:
NDA020353
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2014)
First approved in 2006
Source:
GARDASIL by MERCK AND CO INC DIV MERCK SHARP AND DOHME
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2016)
Source:
NDA207648
(2016)
Source URL:
First approved in 1975
Source:
INTRALIPID 10% by FRESENIUS
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2013)
First approved in 1942
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2016)
Source:
NDA207648
(2016)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01064661: Not Applicable Interventional Completed Abdominal Pain
(2010)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:emilimogene sigulactibac [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04353518: Phase 3 Interventional Unknown status COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
